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ABSTRACT
Objective To characterise the phenotype and genotype
of neonates born small-for-gestational age (SGA; birth
weight <10th centile) who developed hyperinsulinaemic
hypoglycaemia (HH).
Methods Clinical information was prospectively
collected on 27 SGA neonates with HH, followed by
sequencing of KCNJ11 and ABCC8.
Results There was no correlation between the maximum
glucose requirement and serum insulin levels. Serum insulin
level was undetectable in ﬁve infants (19%) during
hypoglycaemia. Six infants (22%) required diazoxide
treatment >6 months. Normoglycaemia on diazoxide <5 mg/
kg/day was a safe predictor of resolved HH. Sequencing of
KCNJ11/ABCC8 did not identify any mutations.
Conclusions Serum insulin levels during hypoglycaemia
taken in isolation can miss the diagnosis of HH. SGA
infants may continue to have hypofattyacidaemic
hypoketotic HH beyond the ﬁrst few weeks of life.
Recognition and treatment of this group of patients are
important and may have important implications for
neurodevelopmental outcome of these patients.
INTRODUCTION
Hyperinsulinaemic hypoglycaemia (HH) is charac-
terised by the unregulated secretion of insulin from
pancreatic β-cells in relation to the blood glucose
concentration. It is the commonest cause of severe
and persistent hypoglycaemia in the neonatal and
infancy periods.1 The genetic basis of congenital
forms of HH involves defects in key genes (com-
monest—ABCC8 and KCNJ11 encoding the two
subunits SUR1 and Kir6.2, respectively), which
regulate insulin secretion from pancreatic β-cells.1
HH may be secondary to certain risk factors (such
as maternal diabetes mellitus, perinatal asphyxia
and small-for-gestational age (SGA)). In 1984,
Collins and Leonard ﬁrst described transient HH in
SGA infants.2 It has not previously been documen-
ted whether the HH observed in infants born SGA
is due to defects in the ABCC8/KCNJ11 genes. The
phenotype of a large cohort of SGA neonates who
developed HH has not been studied previously.
The purpose of the present study was to report on
the phenotype, clinical course and results of the
sequencing of ABCC8/KCNJ11 in a cohort of
infants born SGAwho developed HH.
PATIENTS AND METHODS
We prospectively studied the clinical and biochem-
ical features of 27 SGA (deﬁned as birth weight
<10th centile) neonates with HH who were
admitted to two tertiary paediatric referral centres
(Great Ormond Street Hospital and Bristol Royal
Hospital for Children). Neonates with history of
perinatal asphyxia, Rhesus isoimmunisation and
syndromic forms such as Beckwith-Wiedemann
syndrome were excluded from the study. All were
investigated at the time of clinical and biochemical
hypoglycaemia to establish the diagnosis of HH
and were commenced on diazoxide (5–20 mg/kg/
day). Diazoxide responsiveness was deﬁned as
ability to come off intravenous glucose and main-
tain normoglycaemia during a physiological fast.
Following discharge, they were followed up at
3-monthly intervals in outpatient clinic, where
glycaemic control and diazoxide dose were
reviewed. These infants were readmitted for a
24-h glucose proﬁle and a controlled fast after
stopping diazoxide for 3 days, if home glucose
monitoring indicated no recurrence of hypogly-
caemia on <5 mg/kg/day of diazoxide.1 If home
glucose monitoring revealed hypoglycaemic epi-
sodes, the dose of diazoxide was adjusted and the
trial off diazoxide was postponed until the dose
was <5 mg/kg/day.
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What is already known on this topic
▸ Infants born small-for-gestational age are at an
increased risk to develop transient
hyperinsulinaemic hypoglycaemia (HH).
▸ Mutations in ABCC8/KCNJ11 genes are the
commonest cause of congenital HH.
What this study adds
▸ This largest series of small-for-gestational age
infants who developed hyperinsulinaemic
hypoglycaemia (HH) highlights that
hypofattyacidaemic hypoketotic HH may persist
beyond the ﬁrst few weeks of life.
▸ HH in these infants is diazoxide responsive and
not identiﬁed to be due to mutations in
ABCC8/KCNJ11 genes in this series.
▸ Withdrawal of diazoxide treatment when
glycaemic control is maintained at a dose of
<5 mg/kg/day can be safely recommended.
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Genetics
Genomic DNA was extracted from peripheral leukocytes using
standard procedures and the coding regions and intron/exon
boundaries of the ABCC8 and KCNJ11 genes were ampliﬁed
by PCR (primers available on request). Amplicons were subse-
quently sequenced using the Big Dye Terminator Cycler
Sequencing Kit V.3.1 (Applied Biosystems, Warrington, UK)
according to manufacturer’s instruction and reactions were ana-
lysed on an ABI 3730 Capillary sequencer (Applied Biosystems,
Warrington, UK). Sequences were compared with the reference
sequences (NM_000525.3 and NM_000352.3) using Mutation
Surveyor v3.24 software (SoftGenetics, State College,
Pennsylvania, USA).
RESULTS
Clinical characteristics and course
The phenotypic details of 27 SGA infants with HH are sum-
marised in table 1.
The plasma insulin levels were inappropriately elevated during
hypoglycaemia in 22 infants (81%). The remaining ﬁve infants
(19%) had inappropriately low β-hydroxybutyrate and non-
esteriﬁed fatty acids during hypoglycaemia as supportive biochem-
ical evidence of HH. All infants required glucose infusion rate of
≥8 mg/kg/min to maintain normoglycaemia (median 15.6 mg/kg/
min). There was no correlation found between maximum glucose
infusion rate to maintain normoglycaemia and plasma insulin level
during hypoglycaemia (ﬁgure 1). Most (89%) responded to mild–
moderate doses of diazoxide (5–10 mg/kg/day), with three infants
(11%) needing high doses (15–20 mg/kg/day).
Glucose proﬁle and fasting responses at resolution of
hyperinsulinism
In all, 17 infants (63%) underwent a 24 h glucose proﬁle and con-
trolled fast after stopping diazoxide to demonstrate resolution of
hyperinsulinism. None of these infants recorded hypoglycaemia
during a 24-h glucose proﬁle. All infants maintained blood glucose
concentrations above 3.0 mmol/l at the end of fast appropriate for
their age, with 13 infants maintaining blood glucose concentra-
tions >3.5 mmol/l. All infants showed appropriate plasma insulin
suppression and elevation of plasma β-hydroxybutyrate/non-
esteriﬁed fatty acids as evidence of resolution of HH.
Genetic results
Sequencing did not reveal mutations in ABCC8/KCNJ11 genes
in 25/27 DNA samples analysed.
DISCUSSION
This is the largest case series of SGA neonates with HH that
reports the clinical characteristics and ABCC8/KCNJ11 sequen-
cing results in a cohort of 27 subjects. Collins et al ﬁrst
described transient HH in three SGA infants and subsequently
reported HH in ﬁve of 27 SGA neonates studied, suggesting it is
common in SGA neonates.2 3 It is important to recognise this as
neonates with HH are especially prone to the complications of
hypoglycaemia because of their inability to generate alternative
fuels, such as ketone bodies.
In our study, despite other evidence of hyperinsulinism,
plasma insulin levels were undetectable during hypoglycaemia in
5/27 SGA neonates. We did not ﬁnd any correlation between
the maximum glucose infusion rate required to maintain normo-
glycaemia and plasma insulin levels. This is explained by the
short half-life of insulin of 4–5 min and rapid clearance by the
liver before it reaches peripheral circulation. In a study by Hoe
et al,4 plasma insulin was inappropriately elevated in only 11 of
24 neonates who had transient prolonged neonatal hyperinsu-
linism. Our results corroborate these ﬁndings and highlight the
value of other parameters (apart from plasma insulin) in the
diagnosis of HH.
In this case study of SGA infants referred to two tertiary hos-
pitals with HH, all infants responded to diazoxide, though the
dose was variable ranging from 5 to 20 mg/kg/day. Diazoxide
was successfully stopped in 21 (78%) patients by 6 months of
age. In the remaining six infants, ﬁve needed diazoxide until
10 months of age and one infant needed prolonged treatment
until 22 months. In a study of 26 neonates with hyperinsulinism
which included 7 SGA neonates, HH resolved by a median age
of 181 days (range, 18–403 days).4 Fafoula et al5 also reported
prolonged transient HH up to 9 months in SGA infants.
In our cohort, no recurrence of HH was noticed after stop-
ping diazoxide. This highlights that with the management proto-
col whereby diazoxide was stopped when good glycaemic
control was maintained with diazoxide dose <5 mg/kg/day, the
risk of recurrence of hypoketotic hypoglycaemia brain injury to
these vulnerable infants is avoided.
To our knowledge, no previous study has reported on the
genetic results of SGA neonates who developed HH. In our
study, no mutations in ABCC8/KCNJ11 were identiﬁed in these
SGA infants. However, rarer genetic causes of HH due to muta-
tions in GLUD1, HADH, GCK and HNF4Awere not excluded.
CONCLUSIONS
SGA infants may continue to have hypofattyacidaemic hypoke-
totic HH beyond the ﬁrst few weeks of life. Recognition and
Table 1 Clinical characteristics of 27 small-for-gestational age
infants with hyperinsulinaemic hypoglycaemia
Age at presentation (days)
Median (range) 1 (1–14)
Gestational age (weeks)
Median (range) 37 (32–42)
Birth weight (g)
Median (range) 2300 (1100–3100)
Male (%) 66.6
Ethnic origin (n)
Caucasian 17
Afro-Caribbean 6
Asian 2
Mixed 2
Diazoxide responsive (%) 100
Glucose infusion rate (mg/kg/min)
Median (range) 15.6 (8.0–20.8)
Figure 1 Figure demonstrating the lack of correlation between
maximum glucose infusion rate and plasma insulin concentrations.
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treatment of this group of patients are important and may have
important implications for neurodevelopmental outcome of
these patients. Plasma insulin levels during hypoglycaemia taken
in isolation can miss the diagnosis of HH and hence other para-
meters (such as glucose infusion rates and production of free
fatty acids/ketone bodies during hypoglycaemia) must be consid-
ered in the diagnosis. Withdrawal of diazoxide treatment when
glycaemic control is maintained at a dose of <5 mg/kg/day can
be safely recommended.
Finally, the genetic aetiology of HH in SGA infants is not
understood and, in this study, mutations in the common genes
implicated in the aetiology of congenital hyperinsulinism were
not identiﬁed. Further studies are required to understand the
underlying mechanism of HH in these infants.
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